Mizuho increased its price target for UnitedHealth Group from $410 to $440, maintaining an Outperform rating due to signs that medical cost pressures are easing in the managed care sector. The move reflects confidence that the challenging medical loss ratio shocks of 2025 are subsiding, supported by strong Q1 results and improved medical care ratios. UnitedHealth also raised its full-year 2026 adjusted EPS guidance, signaling optimism for earnings growth. Despite regulatory risks, Mizuho's call suggests the worst may be over for UnitedHealth, making it a potentially attractive investment as the Medicare Advantage rate cycle stabilizes.
A Congressional committee found Medicare Advantage overpays insurers by $212 per enrollee, totaling about $7 billion annually. This overpayment funds insurer profits and supplemental benefits like dental and vision care, which traditional Medicare la...
UnitedHealth's shares surged 20% over the past month, trading around $389, driven by stronger-than-expected Q1 2026 results with revenue up 2% to $111.7 billion and adjusted EPS of $7.23. Despite Berkshire Hathaway's exit from its UNH stake, the comp...
Humana's stock has surged 48% over the past month, outperforming peers like UnitedHealth and Cigna, driven by strong Medicare Advantage (MA) growth and favorable regulatory decisions. The company reported Q1 2026 adjusted EPS of $10.31, beating estim...
